- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| NEURON BIO Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ERASCA | 9,890 | 0,00 % | Erasca, Inc.: Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 21,260 | 0,00 % | Summit Therapeutics leads all large-cap healthcare stocks in YoY CapEx growth | ||
| CG ONCOLOGY | 65,55 | 0,00 % | CG Oncology Inc.: CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026CORE-008 Cohort CX Phase 2 first results of combination... ► Artikel lesen | |
| BEAM THERAPEUTICS | 30,560 | 0,00 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| QIAGEN | 29,170 | +0,15 % | Prognoseschock bei Diagnostikspezialist sorgt für neue Unsicherheit: QIAGEN-Aktie unter Druck: Gewinnwarnung schürt Zweifel an Erholung | QIAGEN überrascht den Markt mit einer deutlichen Senkung der Jahresprognose für 2026. Die schwächelnde Nachfrage und zunehmende Unsicherheiten setzen den Diagnostikkonzern spürbar unter Druck.Gedämpfte... ► Artikel lesen | |
| NUVALENT | 101,94 | -2,05 % | Nuvalent, Inc.: Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC | New Drug Application (NDA) based on data in TKI pre-treated patients from the global ALKOVE-1 Phase 1/2 clinical trial
CAMBRIDGE, Mass., April 7, 2026 /PRNewswire/... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 23,290 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis' ZORYVE (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines | Strong recommendation with high certainty of clinical evidence underscores proven efficacy, safety, and tolerability of ZORYVE cream as a steroid-free topical phosphodiesterase type 4 (PDE4) inhibitorAtopic... ► Artikel lesen | |
| SIONNA THERAPEUTICS | 39,590 | 0,00 % | Sionna Therapeutics, Inc.: Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis | WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm... ► Artikel lesen | |
| DYNE THERAPEUTICS | 18,160 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE Platform at 2026 ASGCT Annual Meeting | ||
| MINERALYS THERAPEUTICS | 25,890 | 0,00 % | Mineralys Therapeutics: TD Cowen startet Coverage mit Kaufempfehlung und sieht Blockbuster-Potenzial | ||
| DISC MEDICINE | 67,26 | 0,00 % | Disc Medicine Inc: Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria | Last participant has been randomized and dosed in the Phase 3 APOLLO study of bitopertin in erythropoietic protoporphyria (EPP)The study size was expanded to 183 participants due to patient and physician... ► Artikel lesen | |
| VERA THERAPEUTICS | 37,110 | 0,00 % | Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer | BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 62,09 | 0,00 % | Mizuho senkt Kursziel für Tarsus Pharmaceuticals wegen Umsatzaussichten auf 100 $ | ||
| NURIX THERAPEUTICS | 17,080 | 0,00 % | Nurix Therapeutics Inc. (NRIX): Leadership in Targeted Protein Degradation Attracts Smart Money | ||
| ALUMIS | 24,020 | 0,00 % | Alumis Inc.: Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis | Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality-of-life improvements and itch... ► Artikel lesen |
NEURON BIO SA gehört der Branche Biotechnologie an.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEURON BIO SA finden Sie auf Wallstreet Online.